A Derby Affair for a Cause
Supporting Children’s Hospital Colorado in their effort to Cure DIPG - Click here for more information
Day Of Details
Step into a world of high society, high stakes, and high-impact philanthropy! The 2221 Society—Denver’s premier philanthropic network—invites you to the Inaugural Derby Party, where tradition meets generosity in spectacular fashion. This is your chance to sip, cheer, and celebrate for a cause that truly matters! DIPG has remained one of the only pediatric cancers in the world for which zero progress has been made. Until now.
Date: May 3, 2025
Location: Four Mile Park, Denver, CO
Time: 2:00 PM – 6:30 PM
Tickets (adults only): $250 per person — Limited availability
What’s In Store
Expect an afternoon filled with sophistication and excitement:
A curated whiskey wall featuring top-shelf selections.
Pick the winning Derby horse with a matching donor doubling every donation placed.
A silent auction with luxury getaways, art, and exclusive experiences.
A showcase of high-end cars alongside horses grazing in the pasture.
Signature mint juleps served all day long.
Many more surprises to come!
Derby Day Attire
Break out your boldest hats, sharpest suits, and your Derby Day best. Picture polo fields, luxury cars, elegant sips, and effortless style & all set against Denver’s beautiful backdrop. Expect the unexpected and bring your competitive spirit (and perhaps the biggest hat in the crowd).
Why We’re Here
All proceeds from this event benefit the Children’s Hospital Colorado through 2221 Society’s Primary Focus - Curing a Previously Untreatable Brain Tumor
Diffuse intrinsic pontine glioma, or DIPG, is a rare, highly aggressive brain tumor that occurs in children, typically between the ages of 5 and 9. Because it grows in the brainstem, which controls the body’s most vital functions, DIPG cannot be operated on. Radiation gives children additional months with their families, but there is no cure. Each year, 300 kids in the U.S. receive this heartbreaking, fatal diagnosis. Most children are given a life expectancy of no more than a year. The terminal nature of DIPG is devastating. Over the past four decades, survival rates for many other cancers have risen dramatically. The cure rate for leukemia, for example, has increased from 11% to 91%. DIPG has remained one of the only pediatric cancers in the world for which zero progress has been made. Until now.
In the past, scientists and pharmaceutical companies have tried various approaches to treating DIPG, usually focused on interrupting the tumor’s growth with small-molecule inhibitors. Unfortunately, these attempts, including more than 200 clinical trials, have not succeeded. The tumor is complex; its biology was not sufficiently understood. But now, after years of studying DIPG—how the tumor works and what the mutation does at its most basic cellular level—Rajeev Vibhakar, MD, Sujatha Venkataraman, PhD, and their team of brain tumor researchers have developed an antibody that targets DIPG in a highly effective way.
